Memocycline - MRS Baseline Analyses Plan
Year: 2026
Type: preprint
Study design: Study Protocol
Abstract: This registration specifies the analysis plan for the magnetic resonance spectroscopy outcomes of the cross-sectional baseline assessment of the MEMOCYCLINE randomized controlled trial. This trial investigates whether guided memory reactivation conducted under minocycline or placebo reduces intrusive trauma- and cocaine-related memories in individuals with posttraumatic stress disorder (PTSD) and cocaine use disorder (CUD). The trial has been prospectively registered on ClinicalTrials.gov (NCT05902819). The present OSF registration does not constitute a second study preregistration but defines the analysis plan for the cross-sectional baseline magnetic resonance spectroscopy data, assessed prior to the intervention with minocycline or placebo. Hence, no treatment/intervention effects are analysed in this preregistration. THEORETICAL BACKGROUND: Dysregulation of glutamate homeostasis is a well-researched phenomenon of addiction. Importantly, continuous cocaine use not only blocks dopamine reuptake in the nucleus accumbens (NAc), but also alters the physical structure of nerve cells in this region. Cocaine-induced dendritic growth increases the capacity of neurons in the NAc core to receive glutamatergic input (Nestler 2005). These findings are in line with the glutamate homeostasis hypothesis of addiction proposed by Kalivas (2009), which highlights the imbalance of glutamatergic prefrontal projections to the NAc as a central mechanism driving chronic substance use. Particularly, chronic cocaine use reduces the membrane levels of the cystine-glutamate exchanger in the NAc core, leading to significantly decreased (approx. 50%) basal extrasynaptic glutamate levels. At a physiological level, the cystine-glutamate exchanger also stimulates metabotropic glutamate 2/3 receptor (mGlu2/3R), decreasing the synaptic glutamate release probability. Upon chronic cocaine consumption, diminished levels of the cystine-glutamate exchanger inhibit the baseline activity of release-regulating mGlu2/3R, and synaptic release of glutamate is increased (Kalivas 2009). Overall, an imbalance of glutamate homeostasis on the cellular and molecular level in the NAc following chronic cocaine use has been proposed. Evidence for glutamatergic imbalance in CUD has been replicated in a limited number of human studies (Engeli et al. 2021; Hulka et al. 2016), however only one study (Engeli et al. 2021) focused on the NAc itself due to methodological challenges targeting deeper brain regions. Another study found elevated levels of total choline concentration ratios in the pregenual anterior cingulate cortex (pgACC) and the right dorsolateral prefrontal cortex (rDLPFC) of chronic cocaine users (Hulka et al. 2016). Similarly, neurometabolic imbalances in emotion-related brain regions such as anterior cingulate cortex (ACC) and amygdala (AMY), as well as in the PFC have been found in PTSD. Several neuroimaging findings in PTSD research indicate hypoactivity of the PFC alongside hyperactivity of the AMY and the dorsal ACC (Hinckley and Danielson 2022; Hayes et al. 2012). These functional alterations are accompanied by neurochemical changes, with elevated glutamate levels observed in the ACC (Averill et al. 2017), while rodent studies show decreased glutamate and glutamine concentrations in the medial PFC (Piggott et al. 2019). Moreover, rodent studies repeatedly suggest glutamatergic projections from the ACC to the basolateral AMY (BLA) to be involved in fear memory encoding and generalization (Jhang et al. 2018; Fang et al. 2018; Ortiz et al. 2019). Relating to this, mouse models of PTSD showed dysregulation of cytoskeleton assembly and myelination pathways in the BLA, central AMY (CeA), and the CA1 of the hippocampus. Additionally, Glx (glutamate+glutamine) metabolism was associated with fear-induced hyperarousal, and alterations in energy metabolism could be observed in the NAc and ACC (Kao 2015). Thus, although considerable evidence supports increased activity of the AMY in PTSD, corresponding glutamate or Glx measurements in the human AMY remain scarce. Moreover, much of the existing PTSD literature has focused primarily on PTSD in veterans or victims of natural disasters, limiting our understanding of whether these findings generalize to other types of trauma (Shin et al. 2006; Young et al. 2018). Not only alterations in the neurotransmitter glutamate or glutamine, but also in other neurometabolites such as N-acetyl-aspartate (NAA) could be observed in individuals with PTSD. NAA, also considered a marker of neuronal health, viability and numbers, is often decreased in psychiatric disorders (Moffett et al. 2007; Schuff et al. 2006). Strikingly, one of the most consistent findings in proton-MRS in patients with PTSD has been a reduction in NAA concentrations in the hippocampus and the ACC (Quadrelli et al. 2018; Maddock and Buonocore 2011), with one exception showing an increase of NAA concentrations in the ACC (Su et al. 2018). However, literature on NAA concentrations in PTSD patients in deeper brain regions such as the AMY is limited (Maddock and Buonocore 2011). Yet, MRS measurement in patients with borderline personality disorder, usually showing a significant trauma history and 35-55% comorbidity with PTSD, showed reduced NAA and creatine levels in the AMY (Hoerst et al. 2010). Additionally, studies involving trauma-exposed individuals with and without PTSD showed associations of time since trauma with neurometabolite concentrations in the AMY and ACC (Wang et al. 2019; Su et al. 2018). Furthermore, there is significant evidence for shared functional and psychological mechanisms between PTSD and SUD (Hinckley and Danielson 2022; Leri et al. 2024; Lguensat et al. 2021). Prevalence of comorbid PTSD and CUD is high, with up to 42.9% of CUD patients meeting criteria for lifetime PTSD, and 22% for current PTSD (S. Back et al. 2000). The majority (95.5%) of comorbid patients report a relationship between PTSD and CUD symptoms, and in particular changes in PTSD symptoms were correlated to changes in subsequent cocaine use (S. E. Back et al. 2006). This raises the question whether those disorders are also molecularly interconnected, perhaps contributing to the high comorbidity of those disorders, as well as their potential to mutually sustain and exacerbate one another (María-Ríos and Morrow 2020; Brady et al. 1998). Despite evidence of functional, psychological and diagnostic overlap of CUD and PTSD, neurobiological research studies about comorbid PTSD and CUD remain scarce. One review focuses on the hypothalamic-pituitary adrenal axis function in comorbid PTSD and CUD (Hadad et al. 2020), and other studies explore the prevalence of comorbidity and its implications for treatment (Wasserman et al. 1997; Leri et al. 2024; María-Ríos and Morrow 2020; McCauley et al. 2012). To our knowledge, no studies have investigated MRS measurements in PTSD, CUD and comorbid PTSD + CUD so far.
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W7172496972
